Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 4/20 | 0.53 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319086 | 0.86 | JAK2 (0.57) | JAK2JAK1NR1D1USP30GPR119 | |
| SCHEMBL8111282 | 0.84 | JAK2 (0.78) | JAK2JAK1STSNR1D1USP30 | |
| SCHEMBL8111279 | 0.84 | JAK2 (0.78) | JAK2JAK1STSNR1D1USP30 | |
| SCHEMBL4329728 | 0.83 | JAK2 (0.51) | JAK2JAK1STSNR1D1USP30 | |
| SCHEMBL24681334 | 0.78 | USP30 (0.52) | JAK2JAK1USP30GPR119MEN1 | |
| SCHEMBL20906990 | 0.78 | USP30 (0.52) | JAK2JAK1USP30GPR119MEN1 | |
| SCHEMBL20281450 | 0.77 | JAK2 (0.72) | JAK2JAK1STSUSP30GPR119 | |
| SCHEMBL651419 | 0.77 | NR1D1 (0.58) | JAK2JAK1STSNR1D1USP30 | |
| SCHEMBL803527 | 0.76 | JAK2 (0.74) | JAK2JAK1STSUSP30GPR119 | |
| SCHEMBL5984831 | 0.76 | STS (0.56) | STSUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | SLC6A2, TPH1, SLC6A3 | JAK2 2020/4885JAK1 1669/4885STS 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.